ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting

18 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting

09 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Mar 2023 16:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

28 Feb 2023 16:02:00 By Nasdaq GlobeNewswire

Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents

21 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference

08 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Feb 2023 16:09:57 By Nasdaq GlobeNewswire

Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis

14 Jan 2023 04:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jan 2023 16:00:00 By Nasdaq GlobeNewswire

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age

19 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older

12 Dec 2022 08:00:53 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Dec 2022 16:01:00 By Nasdaq GlobeNewswire

Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255

05 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology

28 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report

21 Nov 2022 09:15:00 By Nasdaq GlobeNewswire

CORRECTION -- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older

15 Nov 2022 11:09:55 By Nasdaq GlobeNewswire

Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older

15 Nov 2022 08:00:02 By Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

11 Nov 2022 08:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update

08 Nov 2022 16:02:00 By Nasdaq GlobeNewswire

Arcutis to Report Third Quarter Financial Results

25 Oct 2022 16:05:00 By Nasdaq GlobeNewswire